RxDoctor Payments Data

Carl Leto, MD

Ophthalmology · Vienna, VANPI 1528136512

Payments from drug & device makers

$745in general payments, 2019–2025

Across 35 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$388
  • Novartis$126
  • Sun Pharmaceutical Industries Inc.$87
  • Aerie Pharmaceuticals, Inc.$52
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$43
  • Mallinckrodt Hospital Products Inc.$35
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$745 in reported general payments places this provider in the 40th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$314,529
Medicare patients
1,313
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost178$118,578
RestasisCyclosporine34$47,981
CombiganBrimonidine Tartrate/Timolol40$13,219
Cyclosporine15$12,670
Brinzolamide63$12,074
Betoptic SBetaxolol Hcl13$11,993
Alphagan PBrimonidine Tartrate19$8,265
Travoprost37$8,257
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$7,449
Latanoprost500$7,065
SimbrinzaBrinzolamide/Brimonidine Tart14$6,552
RocklatanNetarsudil Mesylat/Latanoprost11$5,622
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat168$4,777
Dorzolamide-TimololDorzolamide/Timolol/Pf21$4,215
Dorzolamide Hcl33$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$388$188,043271 claims
Aerie Pharmaceuticals, Inc.Rocklatan$52$5,62211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Vienna

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →